V enous thromboembolism (VTE) is a leading cause of cardiovascular-related mortality and a disorder with significant genetic predisposition.
independent epidemiological risk factor for VTE, 13 is causally related to risk for VTE.
Methods

Participants
Over a 5-year period beginning in 2006, 503 325 individuals aged 45 to 69 years old were recruited from across the United Kingdom for participation in UK Biobank. At the time of recruitment, a trained healthcare provider conducted verbal interviews to gather baseline characteristics and medical history. In addition, UK Biobank is integrating each participant's EHR into their database, including inpatient International Classification of Diseases, 10th Revision (ICD-10) diagnosis codes and Office of Population and Censuses and Surveys 4th Revision procedure codes. Informed consent was obtained for all participants, and UK Biobank received ethical approval from the Research Ethics Committee (reference number 11/NW/0382). Our study was approved by a local Institutional Review Board at Partners Healthcare (protocol 2013P001840).
VTE Phenotype
Individuals were defined as a VTE case based on at least one of the following criteria:
1. VTE ascertained at baseline by self-report, followed by a verbal interview with a trained nurse to confirm diagnosis; 2. Hospitalization for ICD-10 Code I80. 1 14 Individuals were excluded if they had an ICD-10 diagnosis code of portal vein thrombosis (I81), BuddChiari syndrome (I82.0), superficial or unclear site of thrombophlebitis (I80.0, I80.3, I80.8, I80.9), or known coagulation defects (D68). All other individuals passing quality control (QC) in the genetic analysis (see below) were defined as control participants free of VTE.
UK Biobank Genetic Data
UK Biobank samples were genotyped using either the UK Bileve or UK Biobank Axiom Array. In total, genotypes were available for 152 732 participants, having been performed in 33 separate batches of ≈4700 samples by Affymetrix (High Wycombe, United Kingdom). After phasing of individuals using SHAPEIT-3, genotypes from a reference panel (a combined 1000 Genomes/UK10K reference panel) were imputed (statistically transferred) into UK Biobank participants via IMPUTE3 software. 15 Individual-level QC has been described elsewhere. 16 Briefly, individuals with relatedness of 3rd degree or higher were removed, and an additional 480 individuals were excluded because of more heterozygosity than expected or an excess of missing genotype calls. Of the remaining participants, we included 120 286 individuals of European ancestry (self-identified as Caucasian and European ancestry based on principal components of ancestry). 17 Variant level QC exclusion metrics included: call rate <95%, Hardy-Weinberg equilibrium P value <1×10 −6 , posterior call probability <0.9, imputation quality <0.4, and minor allele frequency <0.005. Sex chromosome and mitochondrial genetic data were excluded from this analysis.
Heritability Calculation
Previous twin/twin-based studies have estimated the heritability of VTE to be ≈50% to 60% 18, 19 ; however, these estimates are potentially inflated owing to their inclusion of related individuals. 20, 21 For this study, h g 2 is defined as the proportion of population variance in disease liability-assuming a liability threshold model 22 -explained by the best linear predictor using genotyped variants. Previous work has demonstrated the need for stringent QC in case-control heritability estimation, 23 and in addition to the above QC, the following single-nucleotide polymorphism (SNP) exclusion criteria were applied to genotyped SNPs: minor allele frequency <0.01, Hardy-Weinberg equilibrium P<0.01, case-control SNP differential call rate P value <0.05, and variant call rate <99.5%. We excluded subjects so that no pair of individuals in our analysis had a relatedness coefficient >0.05 as calculated by the GCTA software. 24 Heritability calculations were performed with the BOLT-REML software, 25 and genotyped SNPs were used for calculation given decreased computational demands while providing minimal deflation in heritability estimates compared with analyses with imputed data. 26 In our restricted maximum likelihood analysis, genotyped SNPs were divided into 5 separate minor allele frequency bins (0.01-0.1, 0.1-0.2, 0.2-0.3, 0.3-0.4, and 0.4-0.5) to account for potential biases, 27 and we further adjusted for age, sex, chip array at runtime, and 20 principal component covariates. Raw restricted maximum likelihood parameter estimates were transformed to h g 2 using linear transformation, 22 assuming that the case ascertainment in the UK Biobank reflected population risk with an estimated disease prevalence (K) of 0.5%. 28, 29 We defined h GWAS 2 as the sum of the variance in liability (V g ) explained for each of the known genome-wide VTE SNPs again invoking the liability threshold method. 30 We used the previously published 9,31,32 risk allele frequencies and odds ratios (ORs) for each variant to calculate the liability threshold for each genotype. We present values estimated using a prevalence estimate (K) of 0.5%.
Genome-Wide Association Analysis
We studied the outcome variable of VTE case status and predictor variable of DNA sequence variant with covariates of age, sex, and chip array at runtime. DNA sequence variant was modeled in an additive fashion (carriage of 0, 1, or 2 copies of the risk allele). We used BOLT-LMM 33 software to perform linear mixed models within the selected individuals. BOLT-LMM was chosen given its ability to adjust for population structure and relatedness while efficiently performing association analysis in a population-based cohort. In addition, we performed a secondary analysis where previously associated SNPs were included as covariates (ie, conditional analysis). To derive effect estimates for each variant that exceeded genome-wide significance or was taken forward for replication, we performed logistic regression (score test) with outcome variable of case status, predictor variable of genotype coded in an additive fashion, and covariates of age, sex, chip array at runtime, and principal components using R and SNPTEST (https://mathgen.stats. ox.ac.uk/genetics_software/snptest/snptest.html) statistical software programs.
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Replication
For 11 SNPs with publicly available summary statistics or that exceeded a P value of 10 −5 in UK Biobank, we obtained replication evidence in collaboration with the INVENT (International Network on Venous Thrombosis) Consortium. In April 2015, INVENT published a VTE GWAS with over 65 000 participants, and summary statistics were obtained from this analysis. 9 Association analysis in INVENT consisted of logistic regression, outcome of VTE, SNPs coded in an additive model, and covariates of age, sex, and principal components. BOLT-LMM results in UK Biobank, and replication results in INVENT were meta-analyzed via a weighted z score method, adjusting for an unbalanced ratio of cases:controls. Logistic regression results for the same top SNPs were meta-analyzed using inverse-variance weighting with fixed effects to refine effect size estimates. The above analyses were performed using the METAL analysis software. 35 A 1-sided P value of <0.05 was required for replication, and we set a statistical threshold of P <5×10 −8 for genomewide significance. VTE Genetics in UK Biobank
Phenome-Wide Association Study
To explore the range of phenotypic consequences associated with VTE risk variants, we conducted a PheWAS using publicly available GWAS summary data and individual-level data for 112 338 participants of European ancestry within UK Biobank. For this analysis, we used a GRS composed of 10 independent (R 2 <0.01) VTE-associated variants (Table I in the Data Supplement) .
To maximize discovery power, we first investigated whether complete SNP data were available for a given phenotype in GWAS summary statistics and then performed an association analysis. For the summary level data, this approach is equivalent to a inverse-variance weighted fixed effects meta-analysis of the effect of each SNP on the trait or outcome of interest, divided by the effect of each SNP on VTE, mathematically equivalent to a previously described GRSbased approach. 36 Of the publicly available disease GWAS summary statistics, only the CARDIoGRAMplusC4D 37 coronary artery disease (CAD) summary data contained all 10 VTE-associated variants in the GRS (http://www.cardiogramplusc4d.org/). For phenotypes meeting the discovery threshold P value using GWAS summary statistics, replication was then performed in UK Biobank (see below).
In UK Biobank, we performed the PheWAS analysis using individual-level data across 37 disorders. Disease status was ascertained at baseline by self-report, followed by a verbal interview with a trained nurse to confirm the diagnosis or appropriate EHR codes. We created a GRS weighting by the effect of each SNP on VTE as previously described. 38 We then examined the effect of the risk score on each trait and outcome per unit increase in VTE odds using a logistic model adjusting for age, sex, principal components, and chip array at runtime.
In discovery, phenotypes were declared to be significantly associated with the GRS if they met a Bonferroni-corrected P value of <0.0014 (0.05/37 traits). For replication, a 1-sided P value of <0.05 was required for statistical significance.
Body Mass Index and VTE: Mendelian Randomization Analysis
We identified 68 independent, genome-wide significant SNPs that were associated with BMI adj among Europeans across both sexes from the GIANT (Genetic Investigation of ANthropometric Traits) consortium (Table II in the Data Supplement). Our primary instrument was a weighted GRS (GRS BMI ) constructed as previously described. 39 We examined the association of a 1 SD increase in the GRS BMI , corresponding to a 1 SD increase in BMI in UK Biobank, with VTE. BMI adj was derived in the UK Biobank through inverse normal transformation of BMI after adjustment for age, age, 2 and sex as performed in the GIANT consortium BMI GWAS. 40 We then performed logistic regression adjusting for age, sex, 10 principal components of ancestry, and chip array at runtime.
Results
Characteristics of the UK Biobank participants according to case-control status are presented in Table 1 . VTE cases tended to be older, female, have a higher BMI, and more likely to be smokers, diabetic, and have a history of cancer. The proportion of overall phenotypic variance explained by genotyped SNPs is estimated to be 29.5% (ie, h g 2 of 29.5±6.5%). After QC, 9 155 762 imputed autosomal variants remained for GWAS in a total of 3290 participants with VTE and 116 868 controls. A total of 214 variants at 5 distinct loci met the genome-wide significance threshold (P<5×10 −8 ) (Figures I and II in the Data Supplement). All 5 have been previously reported. 9 In UK Biobank, the F5 Leiden mutation (rs6025; R534Q) was the top association result ( ), achieved genome-wide significance ( Table 2 ). The rs3136516 variant was identified after conditioning on the prothrombin G20210A (rs1799963) mutation (R 2 =0.007). The proportion of overall phenotypic variance explained by 14 VTE SNPs (12 previously published VTE SNPs as well as the 2 new ones in this study [rs3136516 and rs4602861]) was 5.24% (ie, h GWAS 2 ). Table V in the Data Supplement lists each of the GWAS SNPs with their allele frequencies, ORs, and associated V g used for this calculation.
We conducted a PheWAS for a 10 SNP VTE GRS. Besides VTE, the GRS was associated with CAD in CARDIoGRAMplusC4D summary data (OR, 1.08; 95% CI, 1.05-1.11 per unit increase in VTE odds; P=7.9×10 −9 ) and was replicated in UK Biobank (P<0.05) for a combined OR, 1.08 (95% CI, 1.05-1.10 per unit increase in VTE odds; combined P=1.08×10 −9 ; Figure) . No other phenotype demonstrated statistically significant association with these variants after Bonferroni correction ( Figure III in the Data Supplement). PheWAS phenotype definitions are listed in Table VI in the  Data Supplement. In observational studies, BMI has been shown to be an independent risk factor for VTE 43, 44 ; however, previous genetic analyses assessing causality have failed to provide conclusive results. 45 In UK Biobank, we find that BMI adj is associated with higher odds for VTE (OR, 1.37 for every 1 SD higher BMI adj ; 95% CI, 1.33-1.41; P<2×10 −16 ). However, it is uncertain if this association is causal or because of any of several methodological limitations of observational studies, including reverse causation or confounding. Mendelian randomization leverages the fact that genotypes are randomly assigned at meiosis, are independent of nongenetic confounding, and are unmodified by disease processes; as such, Mendelian randomization is useful for causal inference. We developed an instrument consisting of 68 SNPs previously associated with BMI adj . We first verified that GRS BMI associated with BMI adj in UK Biobank (β=0.84 per SD in GRS BMI ; P<2×10 −16 ). A 1 SD increase in BMI adj corresponded to an absolute increase in BMI of 4.6 kg/m 2 . Genetically elevated BMI (a 1 SD increase) increased the risk of VTE by 57% (OR, 1.57; 95% CI, 1.08-1.97; P=0.003) after adjustment for age, sex, chip array, and principal components (Table 3) .
Discussion
In this study, we leveraged the UK Biobank resource to explore the inherited basis of VTE. We estimated the heritability of VTE to be nearly 30%, performed a GWAS for VTE, which confirmed previous results, and identified 2 new variants. We showed the phenotypic consequences of a VTE GRS. Finally, we provide genetic support for a causal relationship between BMI and VTE.
These findings permit several conclusions. First, EHRbased biobanks provide an enormous potential to aid genetic discovery for complex, common disease. To date, the largest VTE GWAS analyses have been limited to ascertained casecontrol cohorts 9 or direct-to-consumer genetic repositories. 31 In this study, we used a single resource to identify over 3000 VTE cases and 116 000 controls through EHR-based and medical code-based phenotyping, representing approximately one half the number of cases and twice as many controls as the most recent INVENT VTE GWAS analysis. Recent work has questioned the fidelity of such phenotypes 12 ; however, we find that for VTE, cases ascertained through EHR are of high fidelity, as evidenced by the robust replication of previous genetic findings.
Second, these GWAS results provide evidence that genes not related to coagulation may contribute to VTE risk. Early genetic work identified VTE risk variants in genes limited to the coagulation cascade, 8 and later GWAS 41 confirmed these findings. In a meta-analysis, INVENT Consortium investigators provided the first indication that Figure. Phenome-wide association results for the 10 variant venous thromboembolism (VTE) genetic risk score and coronary artery disease. Odds ratio (OR) per unit increase in VTE odds on coronary artery disease within CARDIoGRAMplusC4D data and UK Biobank. For the CARDIOGRAMplusC4D coronary artery disease summary statistics, we performed an inverse-variance weighted fixed effects metaanalysis. Estimates in UK Biobank were derived using logistic regression adjusting for age, sex, chip array, and 10 principal components of ancestry. CI indicates confidence interval. VTE Genetics in UK Biobank genes outside of the coagulation cascade, TSPAN15 and SLC44A2, 9 contribute to VTE risk. In this study, we find that rs4602861 within ZFPM2 also contributes to VTE risk. ZFPM2 is a known transcription factor critical for hematopoiesis and cardiac development. 46, 47 The locus has been associated with circulating vascular endothelial growth factor levels, 48 and recent evidence suggests that vascular endothelial growth factor may be critical for venous thrombus resolution. 49, 50 Taken together, ZFPM2 may influence VTE risk through modulation of circulating vascular endothelial growth factor and disruption of the thrombosis balance within the venous system.
Third, variants conferring risk of VTE may also increase the risk of CAD. Previous work has demonstrated common associations between VTE and CAD at the ABO and SLC44A2 loci. 31 Building in these findings, in our study, a PheWAS using a 10 variant VTE-associated GRS demonstrated an association with increased CAD risk. Although the causal mechanisms underlying atherosclerosis and venous thrombosis are quite different, the downstream activation of the coagulation cascade is common to both myocardial infarction (a direct sequelae of CAD) and VTE. Taken together, our findings suggest that there may be greater overlap in genetic risk variants associated with arterial and venous disease than originally thought.
Fourth, these findings lend genetic support for a causal relationship of obesity with VTE. Previous observational epidemiological work has demonstrated BMI as an independent risk factor for VTE. 13 However, whether this association reflects a causal relationship has been unclear. Klovaite et al 45 performed a Mendelian randomization study examining the BMI exposure and VTE; however, the statistical evidence was limited to a subphenotype of VTE, namely deep vein thrombosis complicated by pulmonary embolism, which represented only 14% of their VTE cases. In this study, human genetic evidence supports a causal role for obesity in risk for VTE. Recent work has suggested that the proinflammatory state induced by obesity may result in impaired fibrinolysis and an increased risk of VTE. 51 As such, therapies targeting the obesity epidemic to reduce the burden of cardiometabolic disease may also mitigate the rising incidence of VTE events. 44 These data should be interpreted in the context of the study's limitations. We focused on participants of European ancestry within UK Biobank, and therefore results may not be generalizable to other populations. The PheWAS may have been underpowered to detect association for the VTE GRS with certain diseases. Last, our phenotype definitions are based largely on ICD and Office of Population and Censuses and Survey codes, and this may result in misclassification of case status. However, such misclassification should reduce statistical power for discovery and bias results toward the null.
Conclusions
EHR-based biobanks provide enormous potential to uncover the genetic basis of common diseases. For the common disease of VTE, the UK Biobank resource enabled us to estimate heritability, perform genetic discovery, explore the range of phenotypic consequences for disease-associated variants, and test causal inference all within a single resource. 
